- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00379015
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy and a monoclonal antibody before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving epirubicin and cyclophosphamide followed by docetaxel and trastuzumab works in treating women with HER2-positive stage IIIB, stage IIIC, or stage IV primary breast cancer.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Determine the pathological complete response in women with HER2-positive stage IIIB-IV breast cancer treated with neoadjuvant epirubicin hydrochloride and cyclophosphamide followed by docetaxel and trastuzumab (Herceptin®).
Secondary
- Determine the clinical response in patients treated with this regimen.
- Determine the recurrence-free survival of patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive epirubicin hydrochloride and cyclophosphamide in weeks 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.
Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Niigata, 일본, 951-8566
- Niigata Cancer Center Hospital
-
Tokyo, 일본, 160-8582
- Keio University Hospital
-
Tokyo, 일본, 173-8605
- Teikyo University School of Medicine
-
-
Ehime
-
Matsuyama-shi, Ehime, 일본, 791-0288
- Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, 일본, 811-1395
- National Kyushu Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Diagnosis of primary breast cancer
- Stage IIIB, IIIC, or IV disease
- No inflammatory disease
- HER2 over-expressing tumor as assessed by immunohistochemistry and/or fluorescent in situ hybridization
- Hormone receptor status known
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- Performance status 0-1
- WBC ≤ 10,000/mm³
- Absolute neutrophil count ≥ 2,000/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.5 g/dL
- SGOT/SGPT ≤ 60 IU/L
- Bilirubin ≤ 1.5 mg/dL
- Creatinine ≤ 1.5 mg/dL
- LVEF ≥ 55%
- No signs of pneumonitis
PRIOR CONCURRENT THERAPY:
- No prior surgery except for biopsy
- No prior or concurrent chemotherapy and/or hormonal therapy
- No prior or concurrent biological therapy
- No prior or concurrent radiotherapy except postoperative radiotherapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: HER2 over-expressing primary breast cancer group
Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses. Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathological complete response
기간: Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab
|
Pathological complete response is assessed in surgical resected specimens of primary tumor from patients who underwent a primary radical surgery in this study.
|
Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical response
기간: From 7 days after the last adoministration of neosdjuvant therapy of Trastuzumab until surgery.
|
Clinical response is assessed as overall response in target lesion of primary tumor from 7 days after the last administration of neoadjuvant therapy of Trastuzumab until surgery.
|
From 7 days after the last adoministration of neosdjuvant therapy of Trastuzumab until surgery.
|
|
Pathological response of axillary lymph nodes
기간: Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab.
|
Pathological response of axillary lymph nodes is assessed in surgical specimens of primary tumor from patients who underwent a primary radical surgery in this study.
|
Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab.
|
|
Recurrence-free survival
기간: 8 years
|
Recurrence-free survival is defined as time from date of enrollment until date of recurrence or death from any cause, whichever comes first.
|
8 years
|
|
Overall survival
기간: 8 years
|
Overall survival is defined as time from date of enrollment until date of death from any cause.
|
8 years
|
|
Adverse event
기간: 70 months
|
Types and severities of adverse events from date of starting protocol treatment until 30 days after date of finishing the treatment are evaluated according to Japanese version of the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) by Translational Research Informatics Center.
|
70 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Tadashi Ikeda, MD, Teikyo University
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000496448
- TUSM-BRI-BC04-01
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .